. Author manuscript; available in PMC: 2013 Feb 28.

Published in final edited form as: N Engl J Med. 2003 Jul 17;349(3):247–257. doi: 10.1056/NEJMoa022289

Table 1.

Characteristics of the Trials.^*

Characteristic	Clinical Trials Group, National Cancer Institute of Canada	North Central Cancer Treatment Group		Gastrointestinal Intergroup, National Cancer Institute	Fondation Française de Cancérologie Digestive
Characteristic	Clinical Trials Group, National Cancer Institute of Canada	Protocol 784852	Protocol 874651	Gastrointestinal Intergroup, National Cancer Institute	Fondation Française de Cancérologie Digestive
Details of trial

Date of first randomization	May 1987	May 1978	February 1988	January 1985	October 1982

Total no. of patients randomized	370	267	111	936	268

Total no. of samples collected and analyzed for microsatellite-instability status	292	66	34	143	35

Eligibility criteria

Age limit	None	None	None	None	≤75 yr

Minimum no. of days between surgery and beginning of chemotherapy	56	35	35	35	35
Adjuvant chemotherapy

Dose of fluorouracil (mg/m²)^†	370	450	425	450	400

Dose of leucovorin (mg/m²)^†	200	—	20	—	200

Dose of levamisole (mg/m²)^†	—	50	—	50	—

Duration of therapy (mo)	6	12	6	12	6

Median follow-up (yr)	6.2	11.6	7.8	8.8	4.9

Modified from the International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators.⁴

^†

The doses are given as milligrams per square meter of body-surface area.